Beam Therapeutics (MEX:BEAM) Tax Provision: MXN0 Mil (TTM As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
69 GF Score
Price MXN655.00
GF Value MXN617.73
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Tax Provision?

Beam Therapeutics MEX:BEAM 69 Tax Provision is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 69/100 and a GF Value™ of MXN617.73 (Fairly Valued). The stock has 6 warning signs investors should review.

Beam Therapeutics's tax provision for the three months ended in Mar. 2026 was MXN0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0 Mil.

Beam Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Tax Provision Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only 0.00 -66.48 -23.19 -0.81 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:BEAM
69GF Score
Beam Therapeutics Inc MEX:BEAM
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of MXN0 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Tax Provision of MXN0 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Tax Provision too high?
Beam Therapeutics' current Tax Provision is MXN0 Mil. Overall, Beam Therapeutics has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Tax Provision compare to ELVN and IDYA?
Beam Therapeutics' Tax Provision of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Tax Provision is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN617.73, compared to a current price of MXN655.00 — trading 6% above its estimated fair value. The current Tax Provision is MXN0 Mil. Beam Therapeutics' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Tax Provision is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN655.00 is trading 6% above its estimated GF Value™ of MXN617.73. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Tax Provision: MXN0 Mil
  • GF Value™: MXN617.73 vs. price of MXN655.00 (6% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
69GF Score

Get the complete analysis for MEX:BEAM

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN655.00
Price
MXN617.73
GF Value